Finance

Lists
DHR:NYSE
Danaher Corp
224,69 USD
+0,83%
(+1,85) 1D
224,69 USD
0,00% (0,00)
After hours
Closed: 14-окт., 16:04:09 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for DHR...
Open
225,00 USD
High
227,86 USD
Low
222,74 USD
Mkt. cap
157,95 млд
Avg. vol.
4,18 млн
Volume
3,60 млн
Dividend
0,71%
Quarterly dividend
0,40 USD
Ex-dividend date
2026-ж., 30-сен.
P/E ratio
39,89
52-wk high
242,80 USD
52-wk low
160,93 USD
EPS
5,63 USD
Beta
0,77
Shares outstanding
702,99 млн
No. of employees
59 миң
Open
225,00 USD
High
227,86 USD
Low
222,74 USD
Mkt. cap
157,95 млд
Avg. vol.
4,18 млн
Volume
3,60 млн
Dividend
0,71%
Quarterly dividend
0,40 USD
Ex-dividend date
2026-ж., 30-сен.
P/E ratio
39,89
52-wk high
242,80 USD
52-wk low
160,93 USD
EPS
5,63 USD
Beta
0,77
Shares outstanding
702,99 млн
No. of employees
59 миң
News stories
From web sources and news partners
Profile
Danaher Corporation is an American healthcare company headquartered in Washington, D.C.. It develops products used for advances in biotechnology, life sciences, and diagnostics. The company operates three divisions: biotechnology, which develops products for the development of therapeutics; life sciences, which develops products to identify causes of disease, new therapies, and to test and manufacture new drugs, vaccines and gene editing technologies; and diagnostics, which develops instruments, consumables, and software and services to diagnose diseases. Danaher was founded in 1984 by brothers Steven Rales and Mitchell Rales; it was named after Danaher Creek in Western Montana, where the brothers came up with the idea for the company while fishing. The company is ranked 180th on the Fortune 500 and 241st on the Forbes Global 2000. Wikipedia
About Danaher Corp
CEORainer M. Blair
Employees59 миң
Founded1969
Headquarters-
SectorHealth care
Analyst ratings
Based on 17 analysts giving stock ratings to DHR in the past 3 months
Strong buy
Buy
16
Hold
1
Sell
0
12-month forecast
Based on 17 Wall Street analysts offering 12 month price targets for DHR in the last 3 months.
Highest
Current 224,69 USD
255,00 USD (+13,49%)
Average
235,31 USD (+4,73%)
Lowest
200,00 USD (-10,99%)
Analyst
Recommendation
Action
Price target
Projected
Date
Daniel Brennan
TD Cowen
Buy
Maintained
255,00 USD
+13,5%
10/13/2026
Kallum Titchmarsh
Morgan Stanley
Buy
Reiterated
240,00 USD
+6,8%
10/13/2026
Lu Li
Bank of America Securities
Buy
Maintained
255,00 USD
+13,5%
10/09/2026
Michael Ryskin
Bank of America Securities
Buy
Maintained
255,00 USD
+13,5%
10/09/2026
Luke Sergott
Barclays
Buy
Maintained
255,00 USD
+13,5%
10/07/2026
Evie Koslosky
Goldman Sachs
Buy
Maintained
250,00 USD
+11,3%
10/05/2026
Dan Leonard
RBC Capital
Buy
Maintained
250,00 USD
+11,3%
10/04/2026
Subbu Nambi
Guggenheim
Buy
Maintained
250,00 USD
+11,3%
10/01/2026
Joanne Wuensch
Citi
Buy
Maintained
230,00 USD
+2,4%
09/21/2026
Tycho Peterson
Jefferies
Buy
Maintained
210,00 USD
-6,5%
09/18/2026
Doug Schenkel
UBS
Buy
Initiated
250,00 USD
+11,3%
09/13/2026
David Westenberg
Piper Sandler
Hold
Maintained
200,00 USD
-11%
07/27/2026
David Toung
Argus Research
Buy
Reiterated
230,00 USD
+2,4%
07/23/2026
Casey Woodring
J.P. Morgan
Buy
Maintained
220,00 USD
-2,1%
07/23/2026
Justin Bowers
Deutsche Bank
Buy
Reiterated
240,00 USD
+6,8%
07/22/2026
Matt Larew
William Blair
Buy
Maintained
-
-
07/22/2026
Daniel Arias
Stifel Nicolaus
Buy
Maintained
220,00 USD
-2,1%
07/22/2026
Patrick B Donnelly
Citi
Buy
Maintained
230,00 USD
+2,4%
07/22/2026
Brandon Couillard
Wells Fargo
Hold
Maintained
195,00 USD
-13,2%
07/22/2026
Aristotelis Moutopoulos
DZ BANK AG
Buy
Maintained
210,00 USD
-6,5%
07/22/2026
Vijay Kumar
Evercore ISI
Buy
Maintained
230,00 USD
+2,4%
07/06/2026
Unknown Analyst
DZ BANK AG
Buy
Initiated
210,00 USD
-6,5%
06/03/2026
Sidharth Sahoo
HSBC
Buy
Maintained
230,00 USD
+2,4%
06/03/2026
Michael Polark
Wolfe Research
Hold
Downgraded
-
-
06/01/2026
Unknown Analyst
RBC Capital
Buy
Initiated
200,00 USD
-11%
05/14/2026
Catherine Ramsey Schulte
Robert W. Baird
Buy
Maintained
245,00 USD
+9%
04/22/2026
Ed Ridley-Day
Rothschild & Co Redburn
Hold
Maintained
205,00 USD
-8,8%
04/17/2026
Unknown Analyst
Goldman Sachs
Buy
Reiterated
230,00 USD
+2,4%
04/14/2026
Next call 7 күндөн кийин
21-окт., шарш., 14:00
Fiscal period
Q3 2026
- / 1,92 USD
Revenue / Est. (USD)
- / 6,56 млд
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance: upcoming earnings
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
2025-ж. сен.
2025-ж. дек.
2026-ж. мар.
2026-ж. июн.
Revenue
6,05 млд
6,84 млд
5,95 млд
6,26 млд
Cost of goods sold
2,53 млд
2,86 млд
2,36 млд
2,61 млд
Cost of revenue
2,53 млд
2,86 млд
2,36 млд
2,61 млд
Research and development expenses
378,00 млн
438,00 млн
387,00 млн
412,00 млн
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
1,89 млд
2,03 млд
1,84 млд
2,01 млд
Operating expense
2,27 млд
2,46 млд
2,23 млд
2,42 млд
Total operating expenses
4,80 млд
5,32 млд
4,59 млд
5,03 млд
Operating income
1,26 млд
1,52 млд
1,36 млд
1,24 млд
Other non operating income
-
-87,00 млн
-
-
EBT including unusual items
1,08 млд
1,37 млд
1,24 млд
1,08 млд
EBT excluding unusual items
1,19 млд
1,39 млд
1,33 млд
1,19 млд
Income tax expense
168,00 млн
190,00 млн
206,00 млн
208,00 млн
Effective tax rate
15,61%
13,84%
16,68%
19,29%
Other operating expenses
-
-
-
-
Net income
908,00 млн
1,20 млд
1,03 млд
870,00 млн
Net profit margin
15,00%
17,51%
17,29%
13,89%
Earnings per share
1,89
2,23
2,06
1,94
Interest and investment income
3,00 млн
13,00 млн
27,00 млн
61,00 млн
Interest expense
-67,00 млн
-55,00 млн
-63,00 млн
-107,00 млн
Net interest expenses
-64,00 млн
-42,00 млн
-36,00 млн
-46,00 млн
Depreciation and amortization charges
-
-
-
-
EBITDA
1,88 млд
2,14 млд
1,99 млд
1,90 млд
Gain or loss from assets sale
-9,00 млн
9,00 млн
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
Google колдонмолору